Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
It comes with a prime focus on infection control and patient flow as the primary infrastructure design aspects - the need of the hour and must-have during a pandemic.
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Subscribe To Our Newsletter & Stay Updated
